Market Closed - Nasdaq Stockholm 11:29:31 2024-04-29 EDT 5-day change 1st Jan Change
37.5 SEK -0.79% Intraday chart for Paxman AB +6.84% +1.90%

Financials

Sales 2023 210M 19.24M 26.3M Sales 2024 * 292M 26.74M 36.55M Capitalization 719M 65.81M 89.95M
Net income 2023 8M 733K 1M Net income 2024 * 34M 3.11M 4.26M EV / Sales 2023 3.33 x
Net cash position 2023 * 19M 1.74M 2.38M Net cash position 2024 * 42M 3.85M 5.26M EV / Sales 2024 * 2.32 x
P/E ratio 2023
83.6 x
P/E ratio 2024 *
21 x
Employees 91
Yield 2023 *
-
Yield 2024 *
-
Free-Float 36.29%
More Fundamentals * Assessed data
Dynamic Chart
Paxman AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Paxman AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
PAXMAN Announces Palmetto GBA Approves First Local Coverage Determination for Scalp Cooling Therapy CI
Paxman AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Paxman AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Paxman AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Paxman AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Paxman Scalp Cooling System Receives EU MDR Certification CI
Paxman AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Paxman AB Announces Its Selection by the SWOG Cancer Research Network for the Paxman Limb Cryocompression System to Be Used in A Prospectively Designed Study Looking At Prevention of Chemotherapy-Induced Peripheral Neuropathy CI
Paxman AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Paxman AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Paxman Launches Enhanced Provider and Patient Assistance Services, as Well as Offering A New Business Model to Health Systems CI
Paxman AB Signs Letter of Interest with Guangzhou Concord Medical Sci-Tech Innovation Center Co. Ltd. to Enter into Distribution and Marketing Agreement CI
Paxman AB Signs New Distribution Agreement with Partner in Serbia CI
More news
1 day-0.79%
1 week+6.84%
1 month+2.46%
3 months+1.35%
6 months+36.36%
Current year+1.90%
More quotes
1 week
34.00
Extreme 34
38.70
1 month
34.00
Extreme 34
38.70
Current year
32.00
Extreme 32
39.70
1 year
22.00
Extreme 22
39.70
3 years
22.00
Extreme 22
74.40
5 years
18.00
Extreme 18
74.40
10 years
9.55
Extreme 9.55
74.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 41 16-12-19
Director of Finance/CFO 44 20-02-29
Chief Tech/Sci/R&D Officer 65 08-12-31
Members of the board TitleAgeSince
Director/Board Member 77 16-11-30
Chairman 70 16-11-30
Director/Board Member 56 16-12-19
More insiders
Date Price Change Volume
24-04-29 37.5 -0.79% 14 530
24-04-26 37.8 +6.78% 66,563
24-04-25 35.4 +2.31% 133
24-04-24 34.6 +0.29% 293
24-04-23 34.5 -1.71% 12,944

Delayed Quote Nasdaq Stockholm, April 29, 2024 at 11:29 am

More quotes
Paxman AB (publ) is a Sweden-based developer of scalp cooling technology. The cooling system aims to reduce the risk of hair loss connected with cytostatic treatment of cancer. The Company offers a stand-alone, mobile electric cooling unit, which markets under the name Paxman Scalp Cooler, which is a liquid-based cooling system that cools down the patients scalp through the silicone hat. The product has two versions - for one or two patients to be cooled at once. Each device contains a built-in touch screen with a menu-controlled graphic user interface to monitor the process. The lightweight system enables patient to participate in other activities. The Company’s primary markets are Great Britain, Scandinavian countries, the Netherlands, Belgium and Australia.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings